Android Apple

Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?

By Yahoo! Finance   |   6 months ago
Should You Hold BioMarin Pharmaceutical (BMRN) Despite Setback?

Scout Investments, Inc, under Carillon Tower Advisers, released the Q1 2024 investor letter for the "Carillon Scout Mid Cap Fund." The letter discusses market trends, highlights like BioMarin Pharmaceutical Inc., and emphasizes AI stocks for higher returns.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.